Excipients are not inert from an analytical point of view. A certificate for a formulated tablet has to account for them, and one that reports a purity figure without saying what the figure is a proportion of is ambiguous. If the premise is wrong, everything after it is decoration.
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one I have a specific reason for asking rather than idle curiosity, and the context is below.
A methods question rather than a substantive one, about oral GLP-1 agonist.
Everyone quotes the same figure and I cannot find anyone who says how it was arrived at. That is not an accusation; it usually means the derivation is somewhere obvious and I have missed it.
The SOUL trial: cardiovascular outcomes trial for oral semaglutide in people with type 2 diabetes and cardiovascular disease or chronic kidney disease. It demonstrates that benefit appears to be a property of the molecule and exposure, not specific to the route.
I had written a reply contradicting the opening post and deleted it. Here is what survived.
On variability: the between-person spread in exposure for oral semaglutide is wide enough that two people on the same dose can have quite different plasma concentrations. That is inherent to the absorption route.
The claim is narrower than it sounds, and deliberately so.
Excipients are not inert from an analytical point of view. A certificate for a formulated tablet has to account for them, and one that reports a purity figure without saying what the figure is a proportion of is ambiguous.
If the premise is wrong, everything after it is decoration.
Oral versus injectable exposure: comparing a 14 mg oral dose with a 0.5 mg injectable dose is comparing apples to a different fruit. The oral bioavailability is low enough that dose numbers are an order of magnitude different and not directly comparable.
This follows post #5 rather than contradicting it.
Orforglipron is a small molecule rather than a peptide, which changes almost everything about how it is made, stored and analysed. Comparing it to oral semaglutide as though they were the same pharmaceutical problem is a category error.
Fasting instructions are not optional advice. Taking the tablet with food or with more than a sip of water measurably reduces absorption. This is the one compound in the class where the instructions genuinely determine the exposure.
Post #5 and I disagree about the size of the effect, not about the direction.
The thirty-minute wait before eating is not conservatism. Food in the stomach materially reduces absorption of the oral product, and the instruction exists because the pharmacokinetic studies measured how much.
If anyone has run this properly I would rather read that than my own guess.
Taking post #9 at face value and following it one step further.
The practical argument for an oral is adherence, and the published adherence data is less flattering than the argument. Daily dosing with fasting requirements is not obviously easier than a weekly injection.
Not a conclusion. A place to stand while looking for one.
Timing consistency matters more for oral dosing than for weekly injection, because absorption depends on the state of the stomach and the state of the stomach varies through the day.
Worth checking against a second source before it gets quoted onward.
Narrowing post #10, because the general version has more than one answer.
The absorption enhancer in the licensed oral product works by transiently raising local gastric pH and promoting absorption across the mucosa. It is the reason the fasting and water-volume instructions are specific rather than cautious.
I would want a second opinion before relying on that.
Oral bioavailability is variable between people. Some people absorb well; others absorb poorly. That inter-individual variation is larger than with injectables and is one reason the trial data for oral formulations receives different treatment.
That is my reading. Someone else read the same page differently and was reasonable.
PIONEER 6 is the cardiovascular outcome trial for oral semaglutide and it enrolled a diabetes population at high cardiovascular risk. Quoting it outside that population is an extrapolation.
Posting it because the silence on this was starting to look like agreement.
Dose numbers for oral formulations are not comparable to injectable ones. The 14 mg oral dose is not equivalent to any injectable dose in the traditional comparison sense. They are different formulations with different pharmacokinetics and cannot be put on the same scale.
It reads as pedantry until the day it does not.
Post #14 answers the question as asked. The question underneath it is different.
Why administration conditions matter for oral semaglutide and not for injectables: the oral formulation depends on a transient pH effect in the stomach. Anything that changes gastric pH or transit time changes absorption. Food does both.
Helpful, and short, which on this subject is harder than long.
Confirming post #17 from a second method, which matters more than confirming it from a second person.
Trial adherence in an oral trial with strict administration requirements is genuinely worse than trial-published data often suggests. That is why the exposure variability in oral formulations is mentioned repeatedly in the discussions here.
Why an oral formulation is a formulation achievement: the molecule is the same but the tablet is novel. Getting a peptide across the gastric epithelium at usable bioavailability is a chemistry problem, not a dose problem.
Anyone with a larger sample, please post it.
Coming back to post #17, because the follow-up matters more than the original answer.
PIONEER programme is phase 3 for oral semaglutide. The trials cover multiple indications and durations. Reading them requires attention to which trial is which because they are not all the same question.
Dose equivalence between oral and injectable formulations is not a simple conversion and no published factor should be used as one. The two were developed and titrated separately.
Staff rationale: Hidden by community flags. The claim about a named supplier was not accompanied by a batch, a date, a method or a document, which R6 requires.
The class is broadening fast enough that anything written here about which orals exist is dated within a year. The mechanisms and the formulation constraints age much more slowly.
Adding the caveat now so it does not have to be extracted later.
The corresponding entry is in the public moderation log. Hidden posts are never deleted.
Picking up post #21: that is the part I would want checked first.
Oral semaglutide's bioavailability is low and variable, which is why the dose numbers are an order of magnitude different from the injectable. That is a formulation consequence and not a difference in potency.
Happy to be the one who is wrong here if it settles the question.
Appreciated. The plain phrasing does more work here than a longer post would.
This follows post #25 rather than contradicting it.
The gastrointestinal tolerability profile of the oral formulation is broadly similar in character to the injectable, which supports the effects being systemic rather than local irritation.
That matches what I was told, which is not the same as knowing it.
Everything in post #25 holds. The case it does not cover is the one I have.
Missed doses behave differently for a daily oral than for a weekly injection. With a short interval you are near a trough rather than perturbing a slowly moving average, and the labelling reflects that.
Take it as a starting point and not as a specification.
Narrowing post #29, because the general version has more than one answer.
PIONEER 6 was a cardiovascular safety trial for oral semaglutide, not an efficacy trial. Non-inferiority for safety was demonstrated. The point estimates favoured the drug but the trial was not designed to establish benefit.
Someone should write this up properly, and it should probably not be me.